Pricing Log in Create free account

Novo Nordisk A/S (NVO) vs Organon & Co. (OGN)

Novo Nordisk A/S and Organon & Co. are both Drug Manufacturers General companies. Novo Nordisk A/S is the larger, with a market value of $134.8B against $3.6B — 37.2× the size. Novo Nordisk A/S trades at the lower P/E: 10.1× against 17.3×. Novo Nordisk A/S grew revenue faster over the last twelve months: 11.1% against −3.21%. Novo Nordisk A/S has the higher net margin (34.1% vs 3.49%) and the higher return on invested capital (29.6% vs 6.26%). Both pay a dividend; Novo Nordisk A/S yields more (4.46% vs 0.58%). Across the 23 metrics below, Novo Nordisk A/S leads on 17 and Organon & Co. on 6.

Valuation

Metric NVO OGN Drug Manufacturers General median
P/E 10.12 17.29 26.51
P/S 3.41 0.60 3.49
P/B 5.28 3.04 5.28
Price to free cash flow 25.76 6.35 21.67
EV/EBITDA 6.99 7.51 14.73
EV/Sales 3.67 1.76 4.15
Earnings yield 9.88% 5.78% 2.41%
Free cash flow yield 3.88% 15.75% 4.07%

Profitability

Metric NVO OGN Drug Manufacturers General median
Gross margin 80.89% 53.12% 73.01%
Operating margin 42.66% 13.63% 18.34%
Net margin 34.09% 3.49% 7.31%
Free cash flow margin 13.25% 9.38% 18.56%
Return on equity 58.84% 20.30% 5.80%
Return on assets 20.52% 1.58% 2.28%
Return on invested capital 29.63% 6.26% 6.26%

Growth

Metric NVO OGN Drug Manufacturers General median
Revenue growth (TTM) 11.14% (3.21%) 6.72%
EPS growth (last fiscal year) 6.40% (78.38%) 21.81%
Revenue growth, 5-year CAGR 19.20% (0.99%) 4.75%
Net income growth, 5-year CAGR 19.16% (38.70%) 0.00%

Health

Metric NVO OGN Drug Manufacturers General median
Debt to equity 0.62 7.17 0.62
Current ratio 0.84 2.02 1.39
Net debt to EBITDA 0.65 5.62 1.15

Dividend

Metric NVO OGN Drug Manufacturers General median
Dividend yield 4.46% 0.58% 2.32%
Payout ratio 0.45 0.11 0.59

Size

Metric NVO OGN Drug Manufacturers General median
Market cap 134.84b 3.62b 129.04b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack